RANKL inhibition with a monoclonal antibody called denosumab has been approved for osteoporosis and skeletal-related events in cancer (Branstetter et al. 2012; Brown-Glaberman and Stopeck 2013) and has been linked to delayed reoccurrence of breast tumors in an adjuvant setting (Gnant et al. 2015). Here, TNFSF11 is linked to cancer.